Targeting JNK3 for the treatment of neurodegenerative disorders
- 1 November 2004
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 9 (21) , 932-939
- https://doi.org/10.1016/s1359-6446(04)03251-9
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125The EMBO Journal, 2004
- Regulation of MAP Kinase Signaling Modules by Scaffold Proteins in MammalsAnnual Review of Cell and Developmental Biology, 2003
- The specificities of protein kinase inhibitors: an updateBiochemical Journal, 2003
- Aberrant Tau Phosphorylation by Glycogen Synthase Kinase-3β and JNK3 Induces Oligomeric Tau Fibrils in COS-7 CellsJournal of Biological Chemistry, 2002
- Identification of the Critical Features of a Small Peptide Inhibitor of JNK ActivityJournal of Biological Chemistry, 2002
- Expanding roles for β-arrestins as scaffolds and adapters in GPCR signaling and traffickingCurrent Opinion in Cell Biology, 2001
- β-Arrestin 2: A Receptor-Regulated MAPK Scaffold for the Activation of JNK3Science, 2000
- Activation of Mitogen-Activated Protein Kinases After Permanent Cerebral Artery Occlusion in Mouse BrainJournal of Cerebral Blood Flow & Metabolism, 2000
- Signal transduction by the c-Jun N-terminal kinase (JNK) — from inflammation to developmentCurrent Opinion in Cell Biology, 1998
- JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation.Genes & Development, 1994